• the management of patients with acute stroke includes
    • diagnosis and specific stroke treatment (recanalization, surgery, etc.)
    • management and prevention of general medical problems
      • cardiac and pulmonary care, fluid and ion balance restoration, metabolic maintenance, blood pressure control
      • prevention and treatment of complications (infection, VTE, intracranial hypertension, bed sores, etc.)
    • evaluation of stroke etiology and initiation of individualized secondary prevention
    • early initiation of rehabilitation (incl. speech therapy, ergotherapy, etc.)
  • the proper management of general conditions and complications is equally important as specific therapy (although the latter may sometimes attract more attention)

Stroke unit care

  • it is recommended to admit the patient to a stroke unit (AHA/ASA 2019 I/A)
    • for a minimum of 24 hours, preferably for 48-72 hours
  • care is provided by a specialized multidisciplinary team
  • treatment in a stroke unit results in a relative reduction in mortality and dependency compared to treatment in a regular ward  [Langhorne, 1997] 
    • treating 100 patients using this approach can result in a reduction of 5 patients who would die or remain dependent (NNT 20)
    • the benefit is universal and applicable to all types of stroke and patients of varying degrees of severity

Basic monitoring

  • oximetry (maintain sat O2 > 94%)
    • use a finger or earlobe sensor
    • oxygen should be provided to maintain oxygen saturation >94%  (AHA/ASA 2019, I/C)
    • do not administer oxygen in nonhypoxic patients (AHA/ASA 2019 III/B-R)
  • blood pressure
    • check BP every 30 minutes in stabilized patient
    • otherwise, proceed per specific protocols (→ Blood pressure management in acute stroke, hypertensive urgency protocols, etc.)
    • hypotension and hypovolemia should be corrected to maintain necessary systemic perfusion levels
    • the usefulness of drug-induced hypertension in patients with AIS is not well established  (AHA/ASA 2019, IIb/B)
  • ECG
    • record 12-lead ECG on admission, then monitor with 3-lead ECG
    • especially infarctions in the right insula can lead to autonomic system failure and cardiac complications (ST depression, T wave inversion, troponin elevation in the laboratory)
    • look for arrhythmias (particularly atrial fibrillation)
  • monitoring the state of consciousness and neurostatus (GCS, NIHSS)
    • adjust the frequency of evaluations based on the patient’s condition and underlying diagnosis (more frequent in extensive SAH, ICH, malignant edema)
    • in unconscious patients, repeatedly assess cranial nerves and brainstem reflexes
  • search for additional symptoms such as headache, nausea, vertigo, singultus

Extended neuromonitoring

  • recommended in patients with severe stroke (~ 24-48h); a 10-20 or 2-4 channel EEG system with adhesive electrodes is used
  • monitoring of SE treatment (always) and depth of anesthesia
  • NCSE diagnosis
    • sensitivity and specificity of standard EEG is low
    • clinical manifestations are none or only subtle and often escape attention (facial twitching, short eyeball deviation, autonomic signs)
  • DDx of non-epileptic seizures
  • monitoring of metabolic coma
  • SSEP (prognostic value in coma vigile)
  • BAEP (brain death diagnosis in patients with decompressive craniectomy)
  • ERP (event-related potential)
    • detection of P300 wave in a coma is associated with a good prognosis
  • indications for ischemic stroke patients are ambiguous
  • probably advantageous in patients with GCS ≤ 8 with extensive hematoma, SAH, or hydrocephalus
  • intraparenchymal or intraventricular sensors are available
  • doppler signs
    • decrease in velocities, increase in resistance and pulsatility index (RI and PI), then disappearance of diastolic flows, and finally systolic spikes or biphasic flow curve → TCCD in the diagnosis of brain death
    • ICP=(10.927* PI)-1.284
    • ↓ vasomotor reactivity
  • B-mode signs
    • optic nerve sheath enlargement or head prominence (transorbital approach)
    • midline shift (transtemporal approach)

→ neurosonology in intensive care

  • a special catheter is inserted into the bulb of the internal jugular vein to monitor venous blood O2 saturation
  • global information is provided, and therefore may not reflect localized issues; take into account body temperature and the effect of medication)
  • normal values: 55-80%
    • SjO2 < 50% with normal arterial O2 saturation indicates either ↓ CBF (e.g., when cerebrovascular resistance is increased) or increased consumption (↑CMRO2)
    • SjO2 > 85% indicates either hyperemia with ↑CBF or ↓CMRO2
  • 2 sensors are placed on the forehead; emitted beams penetrate to about 4 cm
  • from the reflected light, the oxygenation of the brain tissue is derived
  • direct measurement of parenchymal oxygenation near the sensor
  • standard 20-45 mm Hg
  • ischemic threshold (depending on the type of sensor < 15-20 mm Hg)
  • measurement of extracellular metabolite levels in the CNS ( glucose, lactate, pyruvate, lactate/pyruvate ratio, glutamate, glycerol)

Intravascular access

Peripheral venous system
  • ensure intravascular access via a venous cannula in every acute stroke patient (bilaterally if thrombolysis is planned)
    • uncomplicated insertion and management, prefer disinfection with 0.5% chlorhexidine in alcohol during insertion
    • some drugs and concentrated solutions cannot be administered (limit < 600 mosm/l)
    • insertion time: 72-96h
    • remove if not used > 24h or no further use is probable
    • replace in case of local  (e.g., pain, swelling, skin discoloration, skin temperature change, hardening, resistance to flushing) or systemic (fever) complications
  • for longer use, prefer the midline catheter (approx. 14 days – 3 months)
    • can be used for blood sampling
    • drugs with osmolarity < 600 mOsm/l and  nutrition < 800 mOsm/l can be administered
  • when peripheral IV access is required for > 3 months, prefer PICC catheter
    • it is placed under ultrasound guidance in the cavoatrial junction (when maximum P wave is seen in ECG)
    • may be retained for several months
Central venous system
  • central venous catheters (lines) are commonly placed in the internal jugular, subclavian, or femoral veins (usually using a 2 or 3-way cannula)
    •  order chest X-ray to exclude pneumothorax 3 hours after subclavian vein cannulation
  • central catheter enables:
    • administration of all types of drugs and concentrated solutions
    • measuring central venous pressure (CVP)
      • normally 5-12 cm H2O, subtract PEEP in ventilated patients
  • adhere to aseptic treatment incl. sterile cover, and daily checks
  • complications:
    • during insertion: pneumothorax, artery puncture  RTG - pneumothorax po kanylaci v.scl. vpravo
    • late complications: venous thrombosis, catheter sepsis
  • insertion time: 1-3 weeks
  • use PICC or tunneled catheters when prolonged central venous access is required

Major indications for the use of central venous catheters

  • difficult peripheral venous access
  • delivery of certain medications or fluids
    • medications such as vasopressors, chemotherapeutic agents, or hypertonic solutions that damage the peripheral veins
    • additionally, catheters with multiple lumens enable the delivery of several parenteral medications simultaneously
  • prolonged intravenous therapies
  • specialized treatment
    • hemodialysis, plasmapheresis, transvenous cardiac pacing, and invasive hemodynamic monitoring

Classification of intravascular access according to the expected time of insertion

Classification of intravascular access according to the expected time of insertion
â–º Short-term

  • peripheral cannula – 3-4 days
  • central venous catheter – 1-3 weeks
► Mid-term   (→ care)
  • midline catheter – 1-3 months
  • PICC (Peripherally Inserted Central Catheter) – 3 -12 months
â–º Long-term
  • tunneled catheters with cuff – years
  • ports – years

Ventilation and respiration

  • ensure adequate oxygenation (O2 saturation > 94%)
    • SO2S  trial showed no benefit from routine O2 administration ⇒ O2 administration is not recommended in nonhypoxic patients
  • test breathing reflexes and regularly assess the risk of aspiration (many patients have bulbar or pseudobulbar syndrome) → see water swallow test below
    • a common cause of acute respiratory insufficiency is aspiration and/or accumulation of mucus and saliva in the airways due to inadequate expectoration
  • in cases of respiratory infection,  administer antibiotics empirically after collecting sputum and swabs. Adjust the therapy according to cultures and sensitivity results
  • in case of respiratory failure, initiate early intubation and mechanical ventilation
    • before intubation, consider the patient´s prior wishes, general condition, and prognosis
  • Hyperbaric Oxygen Therapy (HBOT) is not recommended, except for stroke caused by air embolization   (Murphy, 2019)   (AHA/ASA 2019 III/B)
    • the limited data show no benefit
    • HBO thus should be offered only in the context of a clinical trial or for individuals with cerebral air embolism
Signs of respiratory failure
  • dyspnoea, involvement of auxiliary respiratory muscles
  • tachycardia
  • respiratory rate > 35/min
  • hypoxemia < 60 mm Hg (7.59 kPa) (at FiO2 0.4 by mask)
  • hypercapnia > 55 mm Hg (7.3 kPa) (except in patients with chronic hypercapnia)

ECG monitoring, arrhythmias

  • acute stroke is associated with an increased risk of cardiac arrhythmias, affecting up to 25% of hospitalized stroke patients
    • the incidence is greatest within the first 24 hours
    • tachycardia is more common than bradycardia
    • arrhythmias are more prevalent in patients with hemispheric lesions
  • while some arrhythmias are benign (such as ventricular/atrial extrasystoles), persistent tachyarrhythmias may lead to hypotension or cardiac failure, potentially contributing to stroke progression
  • atrial fibrillation should be excluded as a potential cause of the stroke
  • ECG monitoring is recommended for ≥ 24 hours (AHA/ASA 2019 I/B-NR)
  • ECG changes are common in acute stroke
    • the ST segment is most commonly affected; these changes may mimic myocardial infarction (ST elevation can be present, but not depression) ⇒ exclude myocardial infarction in such cases
  • the situation is further complicated by frequent elevation in troponin levels, which is usually attributable to cerebral infarction rather than myocardial infarction

Fluids and minerals, glycemia

  • monitor fluid balance every 6-24h and aim to maintain normovolemia or mild hypervolemia
    • measure central venous pressure (CVP) if needed
    • avoid fluid restriction as it increases the risk of ischemic deficit (especially in SAH)
    • hypervolemic hemodilution and vasodilator therapy are not recommended
  • monitor biochemical parameters (ion levels, urea, creatinine, C-reactive protein, hepatic enzymes, and osmolality) as well as complete blood count (CBC) +coagulation profile
    • adjust thefrequency of sampling based on the patient’s condition and any detected abnormalities
  • acid–base balance checks
    • acutely to detect conditions such as hypoxemia, hypercapnia, acidosis/alkalosis
    • stable patients on UPV should be checked  twice daily

Glycemia

  • glucose serves as the primary energy source for the brain; >90% of the brain’s energy derives from the oxidation of glucose. Even during hypoglycemia, glucose remains the most important substrate for brain metabolism
  • the brain/serum glucose ratio (typically 0.6-0.7) drops to 0.2-0.4 in cases of brain injury (esulting in increased sensitivity to hypoglycemia)
  • hyperglycemia (stress hyperglycemia, stress diabetes) is present in up to 2/3 of stroke patients, worsening the outcome of all types of stroke and traumatic brain injuries (TBI)
    • a meta-analysis focus on in-hospital mortality in critically with hyperglycemia showed that even mild hyperglycemia (6.1-8.0 mmol/l) in non-diabetics is associated with a 3.9-fold higher risk of death compared to completely normoglycemic individuals   [Capes, 2000]
  • according to the NICE-SUGAR study, the optimal target glycemia in intensive care is < 10 mmol/L;  hypercorrection to levels < 6 mmol/L increases mortality
    • maintain glycemia around 7.8-10 mmol/L  (140-180 mg/dL) (AHA/ASA 2019 IIa/C-LD)
    • closely monitor and treat hypoglycemia when levels drop below 3.3 mmol (60mg/dL)  (AHA/ASA 2019 I/C-LD)
      • intensive glycemic control can lead to hypoglycemia
      • microdialysis studies indicate that intensive insulin therapy may lead to brain glucose deprivation and and elevated levels of lactate and glutamate  [Vespa, 2006]
  • check glycemia every 6h (glycemic profile); monitor more frequently during continuous insulin administration
  • use repeated boluses of subcutaneous insulin or continuous IV infusion → per insulin protocol

Fever

  • maintain normothermia
  • identify and treat sources of hyperthermia (body temperature >38°C)
  • administer antipyretic medication to hyperthermic patients   (AHA/ASA 219 I/C)
  • the benefit of induced hypothermia is uncertain

Nausea and vomiting

  • most commonly occurs in ICH, SAH, and brainstem ischemia

Prevention and management of GI complications

  • gastrointestinal (GI) complications are common and significantly worsen morbidity and mortality
  • most common complications:
    • stress ulcer
    • gastroesophageal reflux (GER)
    • gastroparesis
    • intestinal paralysis (paralytic ileus)
      • ⇒ X-ray, abdominal SONO or CT
      • endoscopic desufflation
    • constipation/diarrhea
    • singultus
  • the most common cause of GI bleeding is either a preexisting lesion or newly developed “stress ulcer
    • disruption of the integrity of the upper GI mucosa due to extreme physiological stress, typically in critically ill patients
    • often develops within a few hours after the initial insult
    • can result in bleeding or perforation ⇒ ↑ mortality and intensive care stay
    • incidence approx. 3% when on prophylactic medication
  • risk factors for GI bleeding
    • coagulopathies, including iatrogenic
    • history of GI bleeding/peptic ulcer
    • mechanical ventilation > 48h
    • traumatic brain/spinal cord injury
    • sepsis
    • corticosteroids use
    • renal and hepatic impairment
    • malignancy
    • sever stroke
  • prophylaxis should be administered only to patients at increased risk and discontinued in a timely manner (due to the increased risk of nosocomial pneumonia, Clostridium difficile infection, drug interactions, or hepatotoxicity); routine use of PPIs does not reduce mortality
    • proton pump inhibitors (PPIs)OMEPRAZOLE, PANTOPRAZOLE
      • 20-40 mg once daily PO or IV
      • PPIs are more expensive and significantly more effective than H2-blockers [Buendgens, 2016]
    •  use H2 blockers if PPIs are contraindicated
      • FAMOTIDINE 40 mg once daily, or 20 mg twice daily PO
    • SUCRALFATE
      • 1g PO or via nasogastric tube every 6-8 hours
      • used in peptic ulcer prevention and treatment or to reduce hyperphosphatemia
    • antacids
  • initiate enteral nutrition as soon as possible!
  • induced by a clonic contraction of the diaphragm with simultaneous closure of the glottis
  • benign causes predominate in short-term hiccups
    • distention of the esophagus and stomach, intake of carbonated fluids, irritation of the digestive tract with spices)
    • emotions, excitement
    • sudden change in temperature): drinks (hot/cold), shower, air, etc.
  • more serious causes:
    • pulmonary and mediastinal diseases (pneumonia, lung tumors, mediastinitis, and mediastinal tumors)
    • abdominal cavity diseases (direct irritation of the diaphragm – ileus, peritonitis, stomach and liver tumors and metastases, liver abscess, pancreatitis, and pancreatic tumors, etc.)
    • heart diseases (pericarditis, MI)
    • esophageal diseases (oesophageal obstruction by solid food or tumor, or esophagitis)
    • metabolic causes (uremia, diabetes decompensation), acid-base disorders, mineral imbalances (hyponatremia)
    • central (direct or indirect brainstem lesions) – tumors, stroke, trauma
    • alcohol and drugs (dexamethasone, methyldopa, sulfonamides, antiepileptic drugs)
  • severe forms are often resistant to symptomatic treatment
  • treat potential causes
  • pharmacotherapy (see table), including combination therapy (e.g., omeprazole + baclofen +  gabapentin)
  • psychotherapy
  • acupuncture

→ overview of treatment options see here

BACLOFEN
the both peripheral and central effect
PO 5-20 mg every 8-12 hours (max dose 60 mg/d)
Anticonvulsive drugs
gabapentin (NEURONTIN) PO 300 mg every 8 hours
valproate (ORFIRIL, DEPAKINE)
PO up to 15 mg/kg/24h divided into 3-4 doses
Neuroleptics (central effect)
HALOPERIDOL PO  1-4 mg 1-3x daily

  • titrate gradually (sometimes 1-2 mg per night is enough); fewer AEs occur at this dose
chlorpromazine (PLEGOMAZIN)
PO 25-50 mg every 6-8 h (if PO form available)
after 3 days, increase the dose to 25-50mg every 3-4h
Prokinetic drugs
metoclopramide
PO 10 mg every 6-8 hours
PPI (if GER is suspected)
omeprazole
pantoprazole
PO 20-40 mg once daily

Pain management

  • pain is typically present in SAH, less commonly in ICH and ischemic stroke
  • untreated pain may contribute to elevated blood pressure, tachycardia, or patient agitation
  • rule out fractures or dislocations, which are often caused by falls due to sudden paresis

Dysphagia screening, oral hygiene

Nutrition

  • catabolic state is common in the acute phase of stroke
  • the total energy demand depends on the basic metabolic rate (BMR) and other factors
  • early initiation of nutrition (within 24 hours) reduces the risk of various complications (malnutrition increases the risk of infection, muscle loss, etc.)
  • enteral nutrition is preferred; if parenteral nutrition is necessary, use it for the shortest possible duration
  • in patients with significant dysphagia, insert a nasogastric tube (NGS) for the prevention of aspiration bronchopneumonia
  • follow oral hygiene protocols  (AHA/ASA 2018 IIb/B-NR)
  • Harris-Benedict formula basal metabolic rate (BMR) [kcal/day]
    • men = 66,47 + 13,75 x weight [kg] + 5 x height [cm] – 6,67 x age [years]
    • women = 65,10 + 9,56 x weight [kg] + 1,85 x height[cm] – 4,68 x age [years]
    • total energy demand = BMR x A factor x T factor (kcal/day)
    • kJ = 4.18 * kcal
  • for obese people (with a BMI > 30) prefer the Mifflin−St. Jeor (MSJ) equation  → calculator
    • men(kcal/day) = 5 + 10× weight (kg) + 6.25× height (cm) − 5× age (years)
    • women(kcal/day) = −161 + 10× weight (kg) + 6.25× height (cm) − 5× age (years)
A factor
(activity)
immobile patient   1.2
mobile patient   1.3
T factor
(trauma)
surgery
minor-moderate 1.0-1.1
major 1.1-1.2
infection
light 1.0-1.2
moderate 1.2-1.4
severe 1.4-1.8
trauma
1.2-1.35
polytrauma
1.6
burn injury
< 20%     1.0-1.5
20-40%   1.,5-1.85
> 40%     1.85-1.95

Prevention of infection

  • adhere to barrier measures when in contact with the patient, secure careful hand washing by staff
  • follow protocols for the prevention of aspiration and early detection of impaired airway hygiene
  • regularly evaluate the necessity of each invasive access, and replace them regularly
    • risk of complications increases significantly:
      • from day 3 for cannula
      • from day 5 for urinary catheter
      • from day 7 for central venous catheter (CVC)
  • microbiological screening
    • repeated sputum (throat and nasal swab) and urine cultures twice a week in the ICU
    • take cultures after transfer from another department
    • isolate the patient if necessary (especially after  transfers from ICU, neurosurgery)
  • prophylactic administration of antibiotics is not indicated (AHA/ASA 2018 III/B-R)

Early rehabilitation and speech therapy

  • start rehabilitation and ergotherapy ASAP, including early verticalization
    • however, overly aggressive therapy in the first 24h is not beneficial (AVERT study)  (AHA/ASA 2019 III/B-R)
  • mechanical aids have a positive effect  
    • ReStore exosuit was approved by FDA in 6/2019 Exosuit ReStore
  • effect of fluoxetine on improving motor function is not proven
  • timing and intensity of rehabilitation in SAH and ICH must be individualized

Delirium, anxiety, depression

  • search for signs of delirium, depression, or anxiety and treat them properly
  • in patients without depression, fluoxetine therapy is not effective in enhancing poststroke functional status

→ Delirium

Preventing pressure ulcers

  • paralysis and weakness lead to extended periods of bedrest, increasing the chance of pressure sore development
  • pressure sores typically located on the back of the head, shoulders, elbows, sacrum and buttocks, hips, and heels
  • measures for preventing pressure sores are crucial:
    • regular repositioning of the patient (every 2h), physiotherapy, massages
    • skincare
    • adequate hydration and nutrition (monitor protein and albumin levels)
    • early mobilization
    • prevention devices:
      • anti-decubitus mattress  Antidekubitální pomůcky
      • anti-decubitus fleece  Antidekubitální pomůcky   Antidekubitální pomůcky
    • minimize pharmacological sedation for agitated patients

Brain edema, intracranial hypertension

→ Intracranial hypertension
 → Malignant cerebral infarction

Prevention of venous thromboembolism (VTE)

  • deep vein thrombosis is detected in the first 2 weeks in up to 50% of immobile patients  [Brandstater, 1992]

Prophylaxis and management of acute symptomatic seizures

→ see Acute symptomatic seizures

You cannot copy content of this page

Send this to a friend
Hi,
you may find this topic useful:

General management of acute stroke patients
link: https://www.stroke-manual.com/general-management-of-acute-stroke/